Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe

NCT07292454 | Not Yet Recruiting

• 1 other identifier: PAP_RIPH2_2025/01
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD). However, to the best of our knowledge, the composition of gastric and of intestinal microbiome has never been investigated in a population with IBD according to the presence/absence of Helicobacter pylori (H. pylori) in the stomach.

Conditions

HELICOBACTER PYLORI INFECTIONS; Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)

Keywords

intestinal microbioma; gastric microbioma; HELICOBACTER PYLORI INFECTIONS; Inflammatory Bowel Disease

Outcome Measures

Primary Outcomes (1)

• Prevalence of H. pylori infection in patients with Inflammatory Bowel Disease (IBD)

  Presence of Helicobacter pylori infection determined using gastric biopsies collected during clinically indicated upper gastrointestinal endoscopy. Infection status will be confirmed by standard histological assessment performed as part of routine care. The prevalence will be expressed as the proportion of IBD patients with confirmed H. pylori infection among all included IBD patients in the cohort.

  At the time of endoscopic evaluation (baseline only).

Secondary Outcomes (6)

• Demographic characteristics according to H. pylori infection status

  Baseline.

• Clinical characteristics according to H. pylori infection status

  Baseline.

• Biological inflammatory markers according to H. pylori infection status

  Baseline.

• IBD-related treatments according to H. pylori infection status

  Baseline.

• Prevalence of gastric intestinal metaplasia and dysplasia according to H. pylori infection status

  Baseline.

Study Arms (1)

Patients with Inflammatory Bowel Disease

Endoscopy is systematically performed in patients with Inflammatory Bowel Disease (IBD). In accordance with the recommendations of the French National Authority for Health, gastric biopsies are taken during digestive endoscopy as part of routine clinical care. Two additional biopsies (one fundic and one antral) are planned for research purposes, specifically for metagenomic analysis of the gastric microbiome.

Other: Biopsies

Interventions

Biopsies OTHER

Gastric biopsies are taken during digestive endoscopy as part of routine clinical care. Two additional biopsies (one fundic and one antral) are planned for research purposes, specifically for metagenomic analysis of the gastric microbiome.

Patients with Inflammatory Bowel Disease

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients with a confirmed diagnosis of Inflammatory Bowel Disease (Crohn's disease or ulcerative colitis) receiving routine follow-up care at the University Hospital of Guadeloupe. All participants are scheduled to undergo an upper gastrointestinal endoscopy as part of standard clinical management.

You may not qualify if:

• Patients of less than18 years Patients having not given their writing informed consent

Sponsors & Collaborators

• Centre Hospitalier Universitaire de la Guadeloupe: lead

Study Sites (1)

CHU de la Guadeloupe

Pointe-à-Pitre, CHU de La Guadeloupe, 97159, Guadeloupe

Location

MeSH Terms

Conditions

Inflammatory Bowel Diseases; Colitis, Ulcerative

Interventions

Biopsy

Condition Hierarchy (Ancestors)

Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases; Colitis; Colonic Diseases

Intervention Hierarchy (Ancestors)

Cytodiagnosis; Cytological Techniques; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Specimen Handling; Diagnostic Techniques, Surgical; Surgical Procedures, Operative; Investigative Techniques

Central Study Contacts

georgette Saint-Georges, MD

CONTACT

0590891445; georgette.saint-georges@chu-guadeloupe.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 5, 2025
• First Posted: December 18, 2025
• Study Start: December 15, 2025
• Primary Completion (Estimated): December 15, 2026
• Study Completion (Estimated): December 15, 2026
• Last Updated: December 18, 2025

Record last verified: 2025-12

Locations

GU (1)